...
search icon
vyne-img

Vyne Therapeutics Inc, Common Stock

VYNE

NAQ

$1.04

+$0.04

(4%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$20.33M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.33M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.77
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.99 L
$4.3 H
$1.04

About Vyne Therapeutics Inc, Common Stock

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVYNESectorS&P500
1-Week Return-14.75%-1.91%-1.87%
1-Month Return-43.48%-3.82%8.93%
3-Month Return-62.86%-11.56%-2.39%
6-Month Return-64.75%-10.21%-2.41%
1-Year Return-60.46%-9.91%10.88%
3-Year Return-85.32%-0.28%46.93%
5-Year Return-99.4%31.29%94.89%
10-Year Return-99.95%75.9%177.5%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue20.99M14.76M477.00K424.00K501.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":70.29,"profit":true},{"date":"2022-12-31","value":2.27,"profit":true},{"date":"2023-12-31","value":2.02,"profit":true},{"date":"2024-12-31","value":2.39,"profit":true}]
Cost of Revenue1.39M3.35M--4.00K[{"date":"2020-12-31","value":41.58,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":0.12,"profit":true}]
Gross Profit19.60M11.41M477.00K424.00K497.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":58.2,"profit":true},{"date":"2022-12-31","value":2.43,"profit":true},{"date":"2023-12-31","value":2.16,"profit":true},{"date":"2024-12-31","value":2.54,"profit":true}]
Gross Margin93.37%77.31%100.00%100.00%99.20%[{"date":"2020-12-31","value":93.37,"profit":true},{"date":"2021-12-31","value":77.31,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":99.2,"profit":true}]
Operating Expenses133.08M79.44M34.77M29.68M44.14M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":59.69,"profit":true},{"date":"2022-12-31","value":26.13,"profit":true},{"date":"2023-12-31","value":22.3,"profit":true},{"date":"2024-12-31","value":33.17,"profit":true}]
Operating Income(113.47M)(68.03M)(34.30M)(29.26M)(43.64M)[{"date":"2020-12-31","value":-11347500000,"profit":false},{"date":"2021-12-31","value":-6803200000,"profit":false},{"date":"2022-12-31","value":-3429500000,"profit":false},{"date":"2023-12-31","value":-2925800000,"profit":false},{"date":"2024-12-31","value":-4363700000,"profit":false}]
Total Non-Operating Income/Expense(146.74M)(11.36M)363.00K--[{"date":"2020-12-31","value":-40424.52,"profit":false},{"date":"2021-12-31","value":-3128.1,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(255.83M)(73.78M)(33.93M)(27.87M)(39.80M)[{"date":"2020-12-31","value":-25582600000,"profit":false},{"date":"2021-12-31","value":-7377700000,"profit":false},{"date":"2022-12-31","value":-3393200000,"profit":false},{"date":"2023-12-31","value":-2787200000,"profit":false},{"date":"2024-12-31","value":-3980300000,"profit":false}]
Income Taxes(258.00K)(448.00K)13.00K580.00K4.00K[{"date":"2020-12-31","value":-44.48,"profit":false},{"date":"2021-12-31","value":-77.24,"profit":false},{"date":"2022-12-31","value":2.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":0.69,"profit":true}]
Income After Taxes(255.57M)(73.33M)(33.95M)--[{"date":"2020-12-31","value":-25556800000,"profit":false},{"date":"2021-12-31","value":-7332900000,"profit":false},{"date":"2022-12-31","value":-3394500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(255.57M)(73.33M)(33.95M)(29.48M)(39.81M)[{"date":"2020-12-31","value":-25556800000,"profit":false},{"date":"2021-12-31","value":-7332900000,"profit":false},{"date":"2022-12-31","value":-3394500000,"profit":false},{"date":"2023-12-31","value":-2948100000,"profit":false},{"date":"2024-12-31","value":-3980700000,"profit":false}]
Income From Discontinued Operations(29.12M)(29.12M)10.73M--[{"date":"2020-12-31","value":-271.27,"profit":false},{"date":"2021-12-31","value":-271.27,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(255.57M)(73.33M)(33.95M)(28.45M)(39.83M)[{"date":"2020-12-31","value":-25556800000,"profit":false},{"date":"2021-12-31","value":-7332900000,"profit":false},{"date":"2022-12-31","value":-3394500000,"profit":false},{"date":"2023-12-31","value":-2845200000,"profit":false},{"date":"2024-12-31","value":-3983400000,"profit":false}]
EPS (Diluted)(103.50)(23.04)(11.07)(7.04)(0.94)[{"date":"2020-12-31","value":-10350,"profit":false},{"date":"2021-12-31","value":-2304,"profit":false},{"date":"2022-12-31","value":-1107,"profit":false},{"date":"2023-12-31","value":-704,"profit":false},{"date":"2024-12-31","value":-94.22,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VYNE
Cash Ratio 4.09
Current Ratio 4.47

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VYNE
ROA (LTM) -38.37%
ROE (LTM) -66.15%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VYNE
Debt Ratio Lower is generally better. Negative is bad. 0.22
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.78

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VYNE
Trailing PE NM
Forward PE NM
P/S (TTM) 28.65
P/B 0.38
Price/FCF NM
EV/R 10.04
EV/Ebitda 1.84

FAQs

What is Vyne Therapeutics Inc share price today?

Vyne Therapeutics Inc (VYNE) share price today is $1.04

Can Indians buy Vyne Therapeutics Inc shares?

Yes, Indians can buy shares of Vyne Therapeutics Inc (VYNE) on Vested. To buy Vyne Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VYNE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Vyne Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Vyne Therapeutics Inc (VYNE) via the Vested app. You can start investing in Vyne Therapeutics Inc (VYNE) with a minimum investment of $1.

How to invest in Vyne Therapeutics Inc shares from India?

You can invest in shares of Vyne Therapeutics Inc (VYNE) via Vested in three simple steps:

  • Click on Sign Up or Invest in VYNE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Vyne Therapeutics Inc shares
What is Vyne Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Vyne Therapeutics Inc (VYNE) is $4.3. The 52-week low price of Vyne Therapeutics Inc (VYNE) is $0.99.

What is Vyne Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Vyne Therapeutics Inc (VYNE) is 0.38

What is the Market Cap of Vyne Therapeutics Inc?

The market capitalization of Vyne Therapeutics Inc (VYNE) is $20.33M

What is Vyne Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Vyne Therapeutics Inc is VYNE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top